No Data
NurExone's ExoPTEN, Loaded With SiRNA, Demonstrates Ability to Target Injury and Inflammation Sites – New Study
NurExone Announces the Transfer of Manufacturing of the Active Element in ExoPTEN Drug to a Commercial GMP Manufacturer
NurExone Announces Further Expansion of ExoPTEN Patent Coverage
Updates From NurExone: Growth Conference Presentation and Website Relaunch
On Path to First-in-Human Study, NurExone Engages Prominent Expert in Biological Drug Development
NurExone Announces Expansion of ExoPTEN Patent Coverage With Notice of Allowance for Japanese Patent Application
No Data